- The FDA label lists three Zepbound® (tirzepatide) maintenance doses: 5 mg, 10 mg, or 15 mg once a week. Your prescriber picks yours, since the label names no separate Zepbound® maintenance dose after goal weight.
- Stopping usually brings the weight back. In the SURMOUNT-4 trial of 670 adults, people switched to a placebo regained about 14% of their body weight in a year. Those who stayed on Zepbound® lost 5.5% more.
- Wegovy® (semaglutide) follows the same pattern. In a follow-up of 327 STEP 1 trial adults, people regained about two-thirds of their lost weight within a year of stopping, and most health markers slipped back.
- The Zepbound® label includes a lower 5 mg maintenance dose, and the SURMOUNT-MAINTAIN trial found it held more weight off than placebo, though less than the full dose. Dose spacing, microdosing, and tapers are off-label.
Reaching your goal raises two questions. What is the Zepbound® maintenance dose after goal weight? And what happens if you stop it or Wegovy®?
Zepbound® (tirzepatide) is a GIP and GLP-1 medicine, and Wegovy® (semaglutide) is a GLP-1 medicine. The FDA labels and several large trials answer most maintenance questions. Your prescriber sets your dose.
Read on for the labeled doses, what the trials found after people stopped, and when to call your prescriber.
Important safety information
Zepbound® and Wegovy® have a boxed warning about thyroid C-cell tumors. Read the Prescribing Information and Medication Guide that come with your medicine.
What is the Zepbound® maintenance dose after goal weight?
As of the August 2026 label, Zepbound® (tirzepatide) has three maintenance doses for weight: 5 mg, 10 mg, or 15 mg once a week. No separate dose exists for after goal weight, and your prescriber picks yours based on response and tolerability.
Zepbound® is approved to "maintain weight reduction long term." For obstructive sleep apnea (OSA, pauses in breathing during sleep), the maintenance dose is 10 or 15 mg.
| Dose | Label role |
|---|---|
| 2.5 mg | Starting dose only; not maintenance |
| 5 mg | Maintenance for weight |
| 7.5 mg | Step-up dose; not maintenance |
| 10 mg | Maintenance for weight and OSA |
| 12.5 mg | Step-up dose; not maintenance |
| 15 mg | Maintenance for weight and OSA; highest dose |
Table: What the label says each dose is for. Each step-up lasts at least 4 weeks. Source: Zepbound® Prescribing Information, revised August 2026.
Is 2.5 mg or 5 mg Zepbound® a maintenance dose?
A 5 mg Zepbound® dose is a labeled maintenance dose, but 2.5 mg is not. The label says 2.5 mg "is not approved as a maintenance dosage." The 2.5 mg dose is for starting treatment, and 7.5 mg and 12.5 mg are steps of at least 4 weeks on the way to a maintenance dose.
The label does not use the phrase "lowest effective dose." It says that if a maintenance dose is not tolerated, a lower maintenance dose can be considered.
Does stepping down to 5 mg Zepbound® keep the weight off?
Stepping down to 5 mg of Zepbound® kept more weight off than placebo, but less than staying on 10 or 15 mg, in the SURMOUNT-MAINTAIN trial (The Lancet, June 2026).
In SURMOUNT-MAINTAIN, 441 adults took tirzepatide at 10 or 15 mg for 60 weeks. Then 378 of them stayed on that dose, dropped to 5 mg, or switched to placebo for a year.
| Group after week 60 | Weight at week 112 vs start | Needed rescue tirzepatide |
|---|---|---|
| Stayed on 10 or 15 mg | About 22% lower | About 1 in 12 |
| Dropped to 5 mg | About 17% lower | About 1 in 4 |
| Switched to placebo | About 10% lower | About 2 in 3 |
Table: SURMOUNT-MAINTAIN results for the Zepbound® 5 mg step-down (The Lancet, June 2026). People who regained more than half of the weight they had lost were offered tirzepatide again as a "rescue" treatment.
The SURMOUNT-MAINTAIN authors said 5 mg "might provide a valuable alternative to discontinuation," though responses vary. Your prescriber decides whether you stay on your dose or step down.
How do you know your Zepbound® maintenance dose is working?
A Zepbound® maintenance dose is likely working when your weight holds steady and side effects stay manageable. The label notes most nausea, vomiting, and diarrhea happened during dose increases and eased over time. Call your prescriber if your weight climbs for several weeks or strong hunger returns.
Why does Zepbound® seem to stop working?
Weight loss on Zepbound® can hold for years on a steady dose, so a pause on the scale does not by itself mean it has stopped working. A 3-year SURMOUNT-1 analysis (NEJM, March 2025) followed 1,032 adults with obesity and prediabetes. At 176 weeks, their weight stayed about 12% to 20% below the start, versus about 1% on placebo.
Steady weight on a maintenance dose is the goal, not a failure, and some people keep losing. In SURMOUNT-4, people who stayed on Zepbound® after a 36-week lead-in lost 5.5% more over the following 52 weeks. A climb over several weeks is different, and is a reason to call your prescriber.
How does the Wegovy® maintenance dose compare with Zepbound®?
Wegovy® has one recommended maintenance dose, 2.4 mg once a week, while Zepbound® has three: 5, 10, or 15 mg. Like Zepbound®, the Wegovy® label has no separate dose for after goal weight.
The Wegovy® label also allows 1.7 mg. Adults who handle 2.4 mg for at least 4 weeks may go up to 7.2 mg if their prescriber decides more loss is needed.
Yes, people can keep losing weight on the Wegovy® 2.4 mg maintenance dose. In STEP 4 (JAMA, 2021), people who reached 2.4 mg and stayed on it lost about 8% more over 48 weeks.
| Feature | Zepbound® (tirzepatide) | Wegovy® (semaglutide) injection |
|---|---|---|
| Starting dose | 2.5 mg weekly, 4 weeks | 0.25 mg weekly, 4 weeks |
| Maintenance for weight | 5, 10, or 15 mg weekly | 2.4 mg (recommended) or 1.7 mg; adults up to 7.2 mg |
| Other maintenance uses | OSA: 10 or 15 mg | Heart risk: 2.4 or 1.7 mg; MASH (a fatty liver disease): 2.4 mg |
| Pill option | None | 25 mg tablet daily (maintenance dose) |
| Half-life | About 5 to 6 days | About 1 week |
| Missed one dose | Take within 4 days, or skip | Take if the next dose is over 2 days away, or skip |
| Missed 2 or more in a row | No label restart rule | Restart lower and work back up |
Table: Maintenance dosing at a glance. Sources: Zepbound® Prescribing Information (August 2026) and Wegovy® Prescribing Information (June 2026).
What happens when you stop taking Zepbound® or Wegovy®?
In the SURMOUNT-4 trial, adults who lost about 21% of their body weight on Zepbound® and then stopped regained about 14% of their body weight within a year. Those who stayed on Zepbound® lost 5.5% more over the same year. Waist size, blood pressure, and blood sugar also rose again after stopping.
People who stopped Wegovy® regained about two-thirds of their lost weight within a year (STEP 1 extension).
What happened when people stopped Zepbound®?
Fewer than 2 in 10 people who stopped Zepbound® in SURMOUNT-4 (JAMA, 2024) kept at least 80% of their loss, compared with about 9 in 10 who stayed on. The 670 adults with obesity or overweight, without diabetes, had first lost about 21% over 36 weeks on 10 or 15 mg.
What happened when people stopped Wegovy®?
Two trials found that people who stopped taking Wegovy® regained weight.
In the STEP 4 trial (JAMA, 2021), adults on Wegovy® lost about 11% of their body weight over 20 weeks. The 803 participants were then randomly split: those who kept taking Wegovy® lost a further 8% over the next 48 weeks, while those switched to a placebo regained about 7%.
In a 2022 follow-up of 327 STEP 1 adults (Diabetes, Obesity and Metabolism), people who stopped Wegovy® regained about two-thirds of their loss within a year. Their lifestyle program also ended.
How fast does weight come back after stopping Zepbound® or Wegovy®?
Weight came back at about 0.8 kg (almost 2 pounds) a month after people stopped semaglutide or tirzepatide, in a January 2026 BMJ review. That rate comes from 10 treatment groups with 1,776 people.
No trial has directly compared weight regain after stopping Zepbound® versus Wegovy®. But separate trials show that people regain weight after stopping either drug.
| Study | Drug | People | After stopping | Staying on the drug |
|---|---|---|---|---|
| SURMOUNT-4 | Zepbound® | 670 adults | Regained about 14% of body weight in 52 weeks | Lost 5.5% more |
| STEP 4 | Wegovy® | 803 adults | Regained about 7% of body weight in 48 weeks | Lost about 8% more |
| STEP 1 extension | Wegovy® | 327 adults | Regained about two-thirds of the loss in 1 year | Not studied |
| BMJ 2026 review | Semaglutide and tirzepatide | 10 treatment groups, 1,776 people | About 0.8 kg a month; starting weight in about 1.5 years (predicted) | Not studied |
Table: What happened after people stopped. Before stopping, people had lost about 21% over 36 weeks (SURMOUNT-4), 11% over 20 weeks (STEP 4), and 17% over 68 weeks (STEP 1). These studies were not head-to-head, so compare them with care.
What happens in the weeks after your last Zepbound® or Wegovy® dose?
Zepbound® and Wegovy® leave the body slowly, so their effects fade over weeks. Both labels say the drugs lower calorie intake, likely by affecting appetite. Neither label describes appetite after the last dose, but as drug levels fall, that effect is expected to fade.
| Time after last dose | What the evidence shows | Source |
|---|---|---|
| About 1 week | About half the drug is gone | Label half-lives |
| About 4 weeks | Zepbound® mostly gone (estimate) | Zepbound® half-life |
| About 5 to 7 weeks | Wegovy® stays in the blood about this long | Wegovy® label |
Table: Timeline after the last dose. The Zepbound® clearance time is an estimate from its 5 to 6 day half-life.
How long do you stay on Zepbound®, and do you have to take it forever?
You do not have to take Zepbound® forever, but most people in SURMOUNT-4 and the STEP 1 extension regained weight within a year of stopping. There is no set end date. The label approves Zepbound® to "maintain weight reduction long term," and your prescriber reviews the plan with you over time.
The World Health Organization calls obesity a chronic, relapsing disease. Its guideline (JAMA, February 2026) conditionally recommends long-term GLP-1 treatment, noting limited long-term data.
Insurance coverage for long-term Zepbound® use varies by plan, and some plans require prior authorization.
Do the health benefits of Zepbound® or Wegovy® go away after you stop?
Yes, after people stopped Zepbound® in SURMOUNT-4, waist size, blood pressure, blood sugar, and cholesterol rose again. From week 36 to 88, the placebo group saw these changes:
- Waist: grew about 7.8 cm (3 inches), compared with a further 4.3 cm drop in those who stayed on it.
- Blood pressure: systolic (top number) rose about 8 mm Hg, compared with a 2 mm Hg rise in those who stayed on it.
- Blood sugar: HbA1c (3-month average) rose about 0.3 points but held steady in those who stayed on it.
- Cholesterol and triglycerides: both rose.
A later analysis of 308 participants in the SURMOUNT-4 trial (JAMA Internal Medicine, 2026) found that the more weight people regained, the more their waist size, blood pressure, blood sugar, cholesterol and triglycerides rose. Even those who regained less than a quarter of their weight saw systolic blood pressure (top number) rise by about 7 mm Hg.
In the Wegovy® STEP 1 extension (Diabetes, Obesity and Metabolism, 2022), 327 people regained two-thirds of their lost weight in the year after stopping. Blood pressure returned to baseline, blood sugar rose again, and cholesterol and triglyceride gains partly faded but stayed slightly better than placebo.
SURMOUNT-4 and the STEP 1 extension were not designed to measure sleep apnea, heart attack, or stroke. If you take Zepbound® for sleep apnea or Wegovy® to lower heart risk, ask your prescriber what stopping means for you.
Can you stop, taper, or space out Zepbound® or Wegovy® doses?
You can stop Zepbound® or Wegovy® with your prescriber, but only labeled weekly doses have strong evidence for keeping weight off.
| Option | On the FDA label? | Evidence |
|---|---|---|
| Stay on your maintenance dose | Yes | Strong: SURMOUNT-4, STEP 4 |
| Step down to 5 mg Zepbound® | Yes | One large trial (SURMOUNT-MAINTAIN) |
| Go below 5 mg | No; not approved for maintenance | No completed trials |
| Every other week | No; labels use weekly dosing | One case series of 30 adults; no comparison group |
| Every 10 days or microdosing | No | No completed trials |
| Taper, then stop | No taper schedule on either label | No completed trials; a few under way |
| Stop all at once | Label gives no taper schedule | Trials switched straight to placebo; most regained |
Table: Maintenance options and how strong the evidence is.
Can you stop Zepbound® or Wegovy® cold turkey, or should you taper (wean off)?
Yes, you can stop Zepbound® or Wegovy® all at once, since neither label requires a taper or lists withdrawal symptoms, but plan the stop with your prescriber first. In SURMOUNT-4 and STEP 4, people switched straight to placebo, and the main effect was weight regain.
Custom tapers are off-label. No completed clinical trials have reported results on tapering, though a few are under way or planned.
Can you microdose Zepbound® or take it every other week?
Taking Zepbound® every other week, every 10 days, or in microdoses (less than a labeled dose) is off-label, because the label calls for one dose a week. No completed trials have reported results on microdosing or every-10-days dosing.
In one case series (Obesity, 2026), 30 adults on semaglutide or tirzepatide switched to dosing usually every other week at a weight plateau. Weight held over about 36 weeks, but there was no comparison group. The Zepbound® label does let you move your dose day if doses stay at least 3 days apart.
How can you keep weight off after Zepbound® or Wegovy®, whether you stay on it or stop?
Staying on a Zepbound® or Wegovy® maintenance dose has the strongest evidence for keeping weight off. In SURMOUNT-4, people on placebo got the same diet and activity counseling and still regained about 14%.
- Keep a reduced-calorie diet and physical activity: both labels pair the drugs with them.
- Track your weight weekly: a steady rise over several weeks is a reason to call your prescriber.
- Keep regular check-ins: your prescriber can adjust the plan early if weight returns.
- Add structured exercise: one small study (eClinicalMedicine, 2024) found it may help. A year after treatment ended, people who had paired supervised exercise with liraglutide (the drug in Saxenda®) weighed about 5 kg (11 pounds) less than those on liraglutide alone.
- Get behavior support: the World Health Organization (February 2026) conditionally recommends long-term GLP-1 treatment with intensive behavioral therapy.
Is it safe to stay on a Zepbound® or Wegovy® maintenance dose long term?
Yes, Zepbound® and Wegovy® are FDA-approved for long-term use, and the same side effects and risks apply during maintenance. Nausea, diarrhea, vomiting, and constipation are most common.
Zepbound® and Wegovy® both carry a boxed warning: the drugs caused thyroid C-cell tumors in rodents, and it is unknown if they do in people. Do not use them if you or a family member has had medullary thyroid carcinoma (MTC), or if you have MEN 2 (multiple endocrine neoplasia type 2).
- Pancreatitis: can be serious, with severe belly pain.
- Gallbladder problems: more common than with placebo.
- Severe stomach problems: not advised with severe gastroparesis (very slow stomach emptying).
- Kidney injury: mostly after dehydration from vomiting or diarrhea.
- Allergic reactions: serious ones have been reported; do not use either drug after a serious allergic reaction to it.
- Low blood sugar: more likely with insulin or a sulfonylurea (diabetes pill).
- Eye changes: diabetic retinopathy can briefly worsen in people with type 2 diabetes.
- Surgery: neither the Zepbound® nor the Wegovy® label sets a time to stop before surgery. Tell your care team you take Zepbound® or Wegovy® before anesthesia or deep sedation, since stomach contents may rarely be inhaled.
- Pregnancy: stop Zepbound® once pregnancy is recognized, and Wegovy® at least 2 months before a planned one.
- Birth control pills: Zepbound® can make them less reliable for 4 weeks after starting and each dose increase; use a backup or non-pill method then.
When should you see a healthcare provider about Zepbound® or Wegovy®?
Call your prescriber before changing, spacing, or stopping your dose. Also call if:
- You gain weight or your side effects return after you change your dose, stop, or restart Zepbound® or Wegovy®.
- You want to restart after 2 or more missed Wegovy® doses in a row or a long Zepbound® break.
- You notice a neck lump, trouble swallowing, shortness of breath, or lasting hoarseness.
- You have upper right belly pain, fever, or yellow skin or eyes.
- You can't keep fluids down, or you notice vision changes.
- You feel shaky, sweaty, or confused while taking insulin or a sulfonylurea.
- You plan a pregnancy or surgery.
Call 911 or go to the nearest ER for severe belly pain that won't go away, sometimes spreading to your back. Also call 911 for swelling of your face, lips, tongue, or throat, or trouble breathing.
Bottom line
- The Zepbound® label lists 5, 10, and 15 mg maintenance doses, and your prescriber picks yours.
- After stopping Zepbound® or Wegovy®, most people regain much of their lost weight within about a year, and health markers like blood pressure and blood sugar move back toward where they were before treatment.
- A 5 mg step-down has one large trial behind it. Spacing, microdosing, and tapers are off-label.
Frequently asked questions
Is 7.5 mg Zepbound® a maintenance dose?
No, 7.5 mg is a Zepbound® step-up dose, not a maintenance dose. The label lists only 5, 10, and 15 mg for maintenance, and 12.5 mg is also a step-up dose. Your prescriber picks the dose you stay on.
Are there withdrawal symptoms or side effects when you stop Zepbound® or Wegovy®?
The Zepbound® and Wegovy® labels do not list any withdrawal symptoms. The main change seen in trials after stopping was weight regain. In SURMOUNT-4, people who stopped Zepbound® regained about 14% of body weight in a year.
Do you have to restart Zepbound® at a lower dose after a break?
The Zepbound® label does not require a lower restart dose after a break, and it does not say you must start over at 2.5 mg. Your prescriber sets the restart dose. Take one missed Zepbound® dose within 4 days, or skip it. Wegovy® is different: its label says to restart lower after 2 or more missed doses in a row.
What is the maintenance dose for the Wegovy® pill?
The Wegovy® pill maintenance dose is 25 mg once a day, reached after about 3 months of lower doses starting at 1.5 mg. Take it on an empty stomach with up to 4 ounces of water, then wait 30 minutes before eating or drinking. If 25 mg is not tolerated, the label suggests considering the 1.7 mg injection.
Has anyone stopped Zepbound® or Wegovy® and kept the weight off?
Some people keep most of the weight off after stopping, but trials show it is uncommon. In a SURMOUNT-4 analysis of 308 people who stopped Zepbound®, 54 (about 1 in 6) regained less than a quarter of their loss by week 88. A year after stopping Wegovy® in the STEP 1 extension, people averaged about 6% below their starting weight.
peptides.io relies on primary sources such as FDA labels, clinical trial registries, and peer-reviewed journals.
Sources
- 1. Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., Jouravskaya, I., Murphy, M. A., & SURMOUNT-4 Investigators. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial. JAMA, 331(1), 38-48.
- 2. Celletti, F., Farrar, J., & De Regil, L. (2026). World Health Organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults. JAMA, 335(5), 434-438.
- 3. Eli Lilly and Company. (2026). Zepbound® (tirzepatide) injection, for subcutaneous use: Prescribing information (Revised 08/2026). Retrieved September 28, 2026.
- 4. Horn, D. B., Aronne, L. J., Wharton, S., Bays, H. E., le Roux, C. W., Srinath, R., Gomez-Valderas, E., Arad, A. D., Das, S., Dunn, J. P., Ribeiro, A., Glass, L. C., & Lee, C. J. (2026). Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): A multicentre, double-blind, randomised, placebo-controlled trial. The Lancet, 407(10545), 2305-2318.
- 5. Horn, D. B., Linetzky, B., Davies, M. J., Laffin, L. J., Wang, H., Murphy, M. A., Zimner-Rapuch, S., Lau, E., Arad, A. D., & Lee, C. J. (2026). Cardiometabolic parameter change by weight regain on tirzepatide withdrawal in adults with obesity: A post hoc analysis of the SURMOUNT-4 trial. JAMA Internal Medicine, 186(2), 157-167.
- 6. Jastreboff, A. M., le Roux, C. W., Stefanski, A., Aronne, L. J., Halpern, B., Wharton, S., Wilding, J. P. H., Perreault, L., Zhang, S., Battula, R., Bunck, M. C., Ahmad, N. N., Jouravskaya, I., & SURMOUNT-1 Investigators. (2025). Tirzepatide for obesity treatment and diabetes prevention. The New England Journal of Medicine, 392(10), 958-971.
- 7. Jensen, S. B. K., Blond, M. B., Sandsdal, R. M., Olsen, L. M., Juhl, C. R., Lundgren, J. R., Janus, C., Stallknecht, B. M., Holst, J. J., Madsbad, S., & Torekov, S. S. (2024). Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: A post-treatment analysis of a randomised placebo-controlled trial. eClinicalMedicine, 69, 102475.
- 8. Novo Nordisk. (2026). Wegovy® (semaglutide) injection, for subcutaneous use; Wegovy® (semaglutide) tablets, for oral use: Prescribing information (Revised 06/2026). Retrieved September 28, 2026.
- 9. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., Dicker, D., & STEP 4 Investigators. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425.
- 10. West, S., Scragg, J., Aveyard, P., Oke, J. L., Willis, L., Haffner, S. J. P., Knight, H., Wang, D., Morrow, S., Heath, L., Jebb, S. A., & Koutoukidis, D. A. (2026). Weight regain after cessation of medication for weight management: Systematic review and meta-analysis. BMJ, 392, e085304.
- 11. Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., Wadden, T. A., Wharton, S., Yokote, K., Kushner, R. F., & STEP 1 Study Group. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553-1564.
- 12. Wong, M., Wu, A., Garhe, P. K., & Biermann, M. (2026). Reduced-frequency GLP1 therapy maintains weight, body composition, and metabolic syndrome improvements: A case series. Obesity, 34(Suppl 1), 112-120.
Comments